European Biopharmaceutical Enterprises (EBE), the biotech arm of EFPIA, has elected Marc de Garidel president. Mr de Garidel is vice-president south region of Amgen International, based in Zug, Switzerland.
He takes over from Dr Carlo Incerti, senior vice-president global market access at Genzyme, for a two-year term.
EBE has 63 innovative and research-based pharmaceutical and biotech companies as members. It says it is working towards fostering a favorable business and regulatory environment for biopharmaceutical companies of all sizes operating in Europe.
Other top executives elected to the EBE board for the first time in June include Dr Roberto Gradnik, executive vice-president at Merck Serono in Switzerland; Dr Edwin Moses, chairman and CEO of Ablynx (Belgium); Soren Tulstrup, president and CEO of Santaris Pharma (Denmark); Dr Ralf Schumacher, head of biologics research at Roche (Switzerland); and Dr Ignacio Faus, CEO of Palau Pharma (Spain).
Pat O'Mahony continues key role
Arguably one of the most important positions in European regulatory affairs is the chair of the European Medicines Agency's Management Board.
Pat O'Mahoney has just been re-elected chair of that board, for a second three-year term. Mr O'Mahoney is also chief executive of Ireland's regulator, the Irish Medicines Board.
There are important changes under way at the EMA, with its head, executive director Thomas Lonngren, set to retire this year. Keeping the same management board chair may provide continuity during the expected upheavals in the months ahead.
John Davis (j.davis@elsevier.com)
Click here to start your 30-day, risk-free trial of "The Pink Sheet" DAILY – Immediate business intelligence from the company and product level up.
